Drug Trial Radar · NCT01217515
Diltiazem Hydrochloride Cream for Anal Fissure
Last checked: Nov 19, 2026Latest source record: Jul 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
465
Actual
Start
Oct 2010
Primary completion
Mar 2012
Study completion May 2012
Sponsor
- Lead sponsor
- S.L.A. Pharma AGIndustry
- Sponsor type
- Industry
- First posted
- Oct 8, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase III, multicentre, randomised, double blind, placebo-controlled study in subjects having anal fissure (AF) with AF-related pain. Subjects will undertake a 1-week screening period to provide baseline data and for assessment of eligibility. At the Baseline visit (Week 0), eligible subjects (having an average Numerical Rating Scale (NRS) score of \>4 for worst pain associated with or following defaecation) will be randomised on a 1:1:1 basis to one of the three treatment groups. Subjects will receive diltiazem hydrochloride 2% cream or diltiazem hydrochloride 4% cream or placebo cream. Study treatment will be applied in and around the anus, three times daily, for up to 8 weeks. Following the Week 0 Visit, subjects will be contacted by telephone during Week 1 to ensure adequate compliance with study treatment, to ensure that study drug is being tolerated and that any concomitant medications are used at a level consistent with that prior to randomisation. Subjects will return to the clinic for safety and efficacy assessments at Weeks 2, 4, and 8 and receive a follow-up telephone call at Week 12, following cessation of therapy. Concomitant laxatives and stool softeners will be permitted, as needed, during the entire study period (screening and treatment) to ensure that constipation or passage of hard stools does not confound evaluation or improvement of the condition. Fibre supplements will be allowed but should be continued at the baseline level. Instructions on the use of the Interactive Voice Response System (IVRS) diary will be issued to subjects to record fissure-related pain (NRS) and bowel symptoms daily during the 1-week screening period, to confirm eligibility and post-randomisation to record worst anal pain associated with or following defaecation (NRS) and daily overall AF-related pain (NRS). A record of the number of times the subject has defaecated, laxative and analgesic usage will also be made as well as the number of applications of study treatment, any changes to concurrent medications and any Adverse Events (AEs). In addition, at some or all study visits, subjects will record the Patient's Global Impression of Improvement (PGI-I) on a 7 point Likert scale, complete a Short Form 36 (SF-36) quality of life questionnaire and will undergo examination of their AF. Routine blood samples will be taken and the Skin Irritation Score (SIS) recorded for safety evaluations. Subjects may receive permitted medications for pain per Entry Criteria, but these should remain stable, where possible, up to the Week 8 Visit. Introduction of any new medication for AF will not be permitted unless the Investigator deems "rescue" intervention necessary. A subject will be deemed a treatment failure if rescue intervention is required and will have to be withdrawn from the study. Any subject leaving the study following randomisation for any reason will be asked to complete the Early Withdrawal Visit. This includes subjects who withdraw due to the development of AEs or intolerance, as well as subjects who require rescue intervention. These subjects will return for safety follow-up visits at their previously scheduled follow-up assessment appointments. If complete healing has occurred at the 2 or 4 Week visits, (i.e. prior to the end of the 8-week treatment period), subjects will be asked to continue applying the medication for the full 8 week course, up to the final assessment. Following the Week 8 visit (or Early Withdrawal Visit), subjects will be followed up for a further 4 weeks (following cessation of study medication) to note any AEs. All routine blood analyses (haematology and biochemistry) and plasma levels of diltiazem and of its principal metabolites will be analysed by central laboratories.
Conditions
- Chronic Anal Fissure
Interventions
Diltiazem hydrochloride 4% creamDrug
3 times daily
Diltiazem hydrochloride 2% creamDrug
3 times daily
PlaceboOther
3 times daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Average of Worst Anal Pain Associated With or Following Defaecation for Week 4 (for the 7 Treatment Days Immediately Preceding the Week 4 Visit).Time frame: 4 weeks
Locations
27 sites in 6 countries. Site status is shown where the registry gives one.
Vth MHAT
Sofia, Bulgaria
MHAT Alexandrovska EAD
Sofia, Bulgaria
Military Medical Academy
Sofia, Bulgaria
D Rusev
Sofia, Bulgaria
General Hospital for Active Treatment "Stefan Cherkezov"
Veliko Tarnovo, Bulgaria
Dr Kantcho Kostadinov
Sevileva, Sevilieva, Bulgaria
Praxis
Blankenhain, Germany
Praxis
Fürth, Germany
End- und Dickdarm-Zentrum Mannheim
Mannheim, Germany
Gemeinschaftspraxis
Marl, Germany
Practice of Internal Medicine
Wiesbaden, Germany
Kaunas Medical University Clinics
Kaunas, Lithuania
Siauliai Hospital
Šiauliai, Lithuania
UAB Baltic and American Medical and Surgical Clinic
Vilnius, Lithuania
Spitalul Clinic de Urgenta "Prof Dr O Fodor" Cluj
Cluj Nopoca, Romania
Spitalul Clinic de Urgenta "Prof. Dr O Fodor"
Cluj-Napoca, Romania
Spitalul Judetean de Urgenta Deva
Deva, Romania
Institutul de Gastroenterologie si Hepatologie lasi
Lasi, Romania
Spitalul Clinic Judetean de Urgente "Sf.Spiridon" lasi
Lasi, Romania
Cabinet Medical "Dr Lokos" Chirurgie Generala
Miercurea-Ciuc, Romania
Spitalul Clinic Judetean Mures
Tg Mures, Romania
Centrul Medical Tuculanu SRL
Timișoara, Romania
Spitalul Clinic Judetean de Urgenta Timisoara
Timișoara, Romania
Salvo-San-Ciobanca SRL
Zalău, Romania
Hospital Clinico Universitario Lozano Blesa
Zaragoza, Spain
Royal Sussex County Hospital
Brighton, United Kingdom
Derby City General Hospital
Derby, Derbyshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.